RxSight Reports Q4 Revenue Down 33% YoY; Shares Fall 6%

• RxSight's sales and utilization declined due to "adoption challenges" and structural issues. • Company overstated demand for its products. • RxSight unlikely to meet its FY2025 financial guidance. • Class action lawsuit alleges false and misleading statements. • Investors who purchased shares during the class period are encouraged to contact Gross Law Firm. • Appointment as lead plaintiff is not required to participate in any recovery.